Abstract
Granulocyte–macrophage colony-stimulating factor (GM-CSF) is often used to treat leucopenia. Other haematopoietins may increase the number of circulating leucocytes with higher efficiency, but GM-CSF has additional effects that may be far more relevant than its haematopoietic activity. GM-CSF induces differentiation, proliferation and activation of macrophages and dendritic cells which are necessary for the subsequent T helper cell type 1 and cytotoxic T lymphocyte activation. GM-CSF haematopoietic and non-haematopoietic functions have pro-inflammatory and immune regulatory potential to treat a variety of autoimmune diseases and tumours. On the other hand, GM-CSF deficiency leads to various immune dysfunctions and the current utilization of GM-CSF as haematopoietic factor might be an accurate but very incomplete indication for a cytokine with vast clinical potential.
Similar content being viewed by others
Abbreviations
- AML:
-
Acute myeloid leukaemia
- AMØ:
-
Alveolar macrophage
- BM:
-
Bone marrow
- CISH:
-
Cytokine inducible SH2-domain
- DC:
-
Dendritic cell
- GRAP:
-
GM-CSFRα subunit-associated protein
- iNKT:
-
Invariant natural killer T
- IκK:
-
IκB kinase
- MØ:
-
Macrophage
- MAPK:
-
Mitogen-activated kinase-like protein
- NFκB:
-
Nuclear factor kappa-light-chain-enhancer of activated B cells
- IkB:
-
Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor β
- PI3K:
-
Phosphatidylinositol 3 kinase
- PKC:
-
Protein kinase C
- PAP:
-
Pulmonary alveolar proteinosis
- rhGM-CSF:
-
Recombinant human GM-CSF
- rhG-CSF:
-
Recombinant human granulocyte colony-stimulating factor
- STAT:
-
Signal transducers and activators of transcription
- SLAP:
-
SRC-like adapter protein
- TLR:
-
Toll-like receptor
References
Metcalf D. Hematopoietic cytokines. Blood. 2008;111:485–91.
Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci. 1966;44:287–99.
Sheridan JW, Metcalf D. A low molecular weight factor in lung-conditioned medium stimulating granulocyte and monocyte colony formation in vitro. J Cell Physiol. 1973;81:11–23.
Burgess AW, Camakaris J, Metcalf D. Purification and properties of colony-stimulating factor from mouse lung–conditioned medium. J Biol Chem. 1977;252:1998–2003.
Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8:533–44.
Lane TA, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood. 1995;85:275–82.
Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1998;92:4491–508.
Conti L, Gessani S. GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances. Immunobiology. 2008;213:859–70.
Fukuzawa H, Sawada M, Kayahara T, et al. Identification of GM-CSF in Paneth cells using single-cell RT-PCR. Biochem Biophys Res Commun. 2003;312:897–902.
Hamilton JA, Anderson GP. GM-CSF biology. Growth Factors. 2004;22:225–31.
Xing Z, Braciak T, Ohkawara Y, et al. Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation. J Leukoc Biol. 1996;59:481–8.
de Groot RP, Coffer PJ, Koenderman L. Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. Cell Signal. 1998;10:619–28.
Hansen G, Hercus TR, McClure BJ, et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell. 2008;134:496–507.
Matsuguchi T, Zhao Y, Lilly M, et al. The cytoplasmic domain of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor subunit is essential for both GM-CSF-mediated growth and differentiation. J Biol Chem. 1997;272:17450–9.
McClure BJ, Hercus TR, Cambareri BA, et al. Molecular assembly of the ternary granulocyte-macrophage colony-stimulating factor receptor complex. Blood. 2003;101:1308–15.
Sawada M, Itoh Y, Suzumura A, et al. Expression of cytokine receptors in cultured neuronal and glial cells. Neurosci Lett. 1993;160:131–4.
Carr PD, Gustin SE, Church AP, et al. Structure of the complete extracellular domain of the common subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. Cell. 2001;104:291–300.
McClure BJ, Hercus TR, Cambareri BA, et al. Molecular assembly of the ternary granulocyte-macrophage colony-stimulating factor receptor complex. Blood. 2003;101:1308–15.
Hansen G, Hercus TR, Xu Y, et al. Crystallization and preliminary X-ray diffraction analysis of the ternary human GM-CSF receptor complex. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008;64:711–4.
Choi JK, Kim KH, Park H, et al. Granulocyte macrophage-colony stimulating factor shows anti-apoptotic activity in neural progenitor cells via JAK/STAT5-Bcl-2 pathway. Apoptosis. 2011;16:127–34.
O’Mahony DS, Pham U, Iyer R, et al. Differential constitutive and cytokine-modulated expression of human Toll-like receptors in primary neutrophils, monocytes, and macrophages. Int J Med Sci. 2008;5:1–8.
Tanimoto A, Murata Y, Wang KY, et al. Monocyte chemoattractant protein-1 expression is enhanced by granulocyte-macrophage colony-stimulating factor via Jak2-Stat5 signalling and inhibited by atorvastatin in human monocytic U937 cells. J Biol Chem. 2008;283:4643–51.
Liontos LM, Dissanayake D, Ohashi PS, et al. The Src-like adaptor protein regulates GM-CSFR signalling and monocytic dendritic cell maturation. J Immunol. 2011;186:1923–33.
Domen J, Weissman IL. Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, Kitl/c-Kit signalling the other. J Exp Med. 2000;192:1707–18.
Chen J, Cárcamo JM, Golde DW. The alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor interacts with c-Kit and inhibits c-Kit signalling. J Biol Chem. 2006;281:22421–6.
Lilly MB, Zemskova M, Frankel AE, et al. Distinct domains of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit mediate activation of Jak/Stat signalling and differentiation. Blood. 2001;97:1662–70.
Crosier KE, Wong GG, Mathey-Prevot B, et al. A functional isoform of the human granulocyte/macrophage colony-stimulating factor receptor has an unusual cytoplasmic domain. Proc Natl Acad Sci USA. 1991;88:7744–8.
Raines MA, Liu L, Quan SG, et al. Identification and molecular cloning of a soluble human granulocyte-macrophage colony-stimulating factor receptor. Proc Natl Acad Sci USA. 1991;88:8203–7.
Leukine® Prescribing information. Available at http://products.sanofi.us/Leukine/Leukine.html Accessed on September 2013.
Jiang D, Schwarz H. Regulation of granulocyte and macrophage populations of murine bone marrow cells by G-CSF and CD137 protein. PLoS One. 2010;5:e15565.
Crawford J, Armitage J, Balducci L, et al. Myeloid growth factors. J Natl Compr Canc Netw. 2009;7:64–83.
Kelsen JR, Rosh J, Heyman M, et al. Phase I trial of sargramostim in pediatric Crohn’s disease. Inflamm Bowel Dis. 2010;16:1203–8.
The FDA Safety Information and Adverse Event Reporting Program, 2008. Leukine safety information Available at http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm090918.htm, Accessed on October 2013.
Martinez-Moczygemba M, Doan ML, Elidemir O, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFR{alpha} gene in the X chromosome pseudoautosomal region 1. J Exp Med. 2008;205:2711–6.
Hamilton JA, Whitty GA, Stanton H, et al. Effects of macrophage-colony stimulating factor on human monocytes: induction of expression of urokinase-type plasminogen activator, but not of secreted prostaglandin E2, interleukin-6, interleukin-1, or tumour necrosis factor-alpha. J Leukoc Biol. 1993;53:707–14.
Takahashi GW, Andrews DF 3rd, Lilly MB, et al. Effect of granulocyte-macrophage colony-stimulating factor and interleukin-3 on interleukin-8 production by human neutrophils and monocytes. Blood. 1993;81:357–64.
Selgas R, Fernández de Castro M, Jiménez C, Selgas R, et al. Immunomodulation of peritoneal macrophages by granulocyte-macrophage colony-stimulating factor in humans. Kidney Int. 1996;50:2070–8.
Hart PH, Whitty GA, Piccoli DS, et al. Synergistic activation of human monocytes by granulocyte-macrophage colony-stimulating factor and IFN-gamma. Increased TNF-alpha but not IL-1 activity. J Immunol. 1988;141:1516–21.
Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, et al. Correction of granulocytopenia in Felty’s syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood. 1989;74:2769–70.
de Vries EG, Willemse PH, Biesma B, et al. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet. 1991;338:517–8.
Bischof RJ, Zafiropoulos D, Hamilton JA, et al. Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM)-CSF: evidence of macrophage infiltration and local proliferation. Clin Exp Immunol. 2000;119:361–7.
Campbell IK, Bendele A, Smith DA, et al. Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann Rheum Dis. 1997;56:364–8.
Burmester GR, Weinblatt ME, McInnes IB, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis. 2013;72:1445–52.
Mudzinski SP, Christian TP, Guo TL, et al. Expression of HLA-DR (major histocompatibility complex class II) on neutrophils from patients treated with granulocyte-macrophage colony-stimulating factor for mobilization of stem cells. Blood. 1995;86:2452–3.
Fanger NA, Liu C, Guyre PM, et al. Activation of human T cells by major histocompatibility complex class II expressing neutrophils: proliferation in the presence of superantigen, but not tetanus toxoid. Blood. 1997;89:4128–35.
Herold S, Mayer K, Lohmeyer J. Acute lung injury. How macrophages orchestrate resolution of inflammation and tissue repair. Front Immunol. 2001;2:6.
Cakarova L, Marsh LM, Wilhelm J, et al. Macrophage tumor necrosis factor-alpha induces epithelial expression of granulocyte-macrophage colony-stimulating factor: impact on alveolar epithelial repair. Am J Respir Crit Care Med. 2009;180:521–32.
Krausgruber T, Blazek K, Smallie T, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol. 2011;12:231–8.
Miah MA, Yoon CH, Kim J, et al. CISH is induced during DC development and regulates DC-mediated CTL activation. Eur J Immunol. 2012;42:58–68.
Hornell TM, Beresford GW, Bushey A, et al. Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor. J Immunol. 2003;171:2374–83.
McCormick S, Santosuosso M, Zhang XZ, et al. Manipulation of dendritic cells for host defence against intracellular infections. Biochem Soc Trans. 2006;34:283–6.
Moldenhauer LM, Keenihan SN, Hayball JD, et al. GM-CSF is an essential regulator of T cell activation competence in uterine dendritic cells during early pregnancy in mice. J Immunol. 2010;185:7085–96.
Hesske L, Vincenzetti C, Heikenwalder M, et al. Induction of inhibitory central nervous system-derived and stimulatory blood-derived dendritic cells suggests a dual role for granulocyte-macrophage colony-stimulating factor in central nervous system inflammation. Brain. 2010;133(Pt 6):1637–54.
Sonderegger I, Iezzi G, Maier R, et al. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med. 2008;205:2281–94.
Biondo M, Nasa Z, Marshall A, Toh BH, Alderuccio F. Local transgenic expression of granulocyte macrophage-colony stimulating factor initiates autoimmunity. J Immunol. 2001;166(3):2090–9.
Kim DH, Sandoval D, Reed J, et al. The role of GM-CSF in adipose tissue inflammation. Am J Physiol Endocrinol Metab. 2008;295:E1038–46.
Exley MA, Koziel MJ. To be or not to be NKT: natural killer T cells in the liver. Hepatology. 2004;40:1033–40.
Brochériou I, Maouche S, Durand H, et al. Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. Atherosclerosis. 2011;214:316–24.
Saitoh T, Kishida H, Tsukada Y, et al. Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris. J Am Coll Cardiol. 2000;35:655–65.
Oren H, Erbay AR, Balci M, et al. Role of novel biomarkers of inflammation in patients with stable coronary heart disease. Angiology. 2007;58:148–55.
Kellar RS, Lancaster JJ, Thai HM, et al. Antibody to granulocyte-macrophage colony-stimulating factor reduces the number of activated tissue macrophages and improves left ventricular function following myocardial infarction in a rat coronary-artery ligation model. J Cardiovasc Pharmacol. 2011;57:568–74.
Sugiyama Y, Yagita Y, Oyama N, et al. Granulocyte colony-stimulating factor enhances arteriogenesis and ameliorates cerebral damage in a mouse model of ischemic stroke. Stroke. 2011;42:770–5.
Tu J, Karasavvas N, Heaney ML, et al. Molecular characterization of a granulocyte macrophage-colony-stimulating factor receptor alpha subunit-associated protein. GRAP Blood. 2000;96:794–9.
Stösser S, Schweizerhof M, Kuner R. Hematopoietic colony-stimulating factors: new players in tumor-nerve interactions. J Mol Med. 2011;89:321–9.
Ding DX, Rivas CI, Heaney ML, et al. The alpha subunit of the human granulocyte-macrophage colony-stimulating factor receptor signals for glucose transport via a phosphorylation-independent pathway. Proc Natl Acad Sci USA. 1994;91:2537–41.
Vadhan-Raj S, Keating M, LeMaistre A, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987;317:1545–52.
Schweizerhof M, Stösser S, Kurejova M, et al. Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med. 2009;15:802–7.
Khaled YS, Ammori BJ, Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol. 2013;91:493–502.
Zhang Y, Cheng S, Zhang M, et al. High-infiltration of tumor-associated macrophages predicts unfavorable clinical outcome for node-negative breast cancer. PLoS One. 2013;8:e76147.
Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787–95.
Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, et al. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol. 2012;2012:948098.
Egea L, Hirata Y, Kagnoff MF. GM-CSF: a role in immune and inflammatory reactions in the intestine. Expert Rev Gastroenterol Hepatol. 2010;4:723–31.
Hirata Y, Egea L, Dann SM, et al. GM-CSF-facilitated dendritic cell recruitment and survival govern the intestinal mucosal response to a mouse enteric bacterial pathogen. Cell Host Microbe. 2010;7:151–63.
Brosbøl-Ravnborg A, Hvas CL, Agnholt J, et al. Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn’s disease by nucleotide oligomerization domain 2-dependent and -independent pathways. Clin Exp Immunol. 2009;155:487–95.
Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn’s disease. N Engl J Med. 2005;352:2193–201.
Valentine JF, Fedorak RN, Feagan B, et al. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn’s disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut. 2009;58:1354–62.
Tazawa R, Trapnell BC, Inoue Y, et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2010;181:1345–54.
Kleff V, Sorg UR, Bury C, et al. Gene therapy of beta(c)-deficient pulmonary alveolar proteinosis (beta(c)-PAP): studies in a murine in vivo model. Mol Ther. 2008;16:757–64.
Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670–9.
Olivares J, Kumar P, Yu Y, et al. Phase I trial of TGF-{beta}2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res. 2011;17:183–92.
Bradbury PA, Shepherd FA. Immunotherapy for lung cancer. J Thorac Oncol. 2008;3:S164–70.
Holt GE, Disis ML. Immune modulation as a therapeutic strategy for non-small-cell lung cancer. Clin Lung Cancer. 2009;9:S13–9.
Staff C, Mozaffari F, Haller BK, et al. A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. Vaccine. 2011;29:6817–22.
Garcia JA, Mekhail T, Elson P, et al. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma. BJU Int. 2012;109:63–9.
Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253:328–35.
Wang L, Qi X, Sun Y, et al. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity. Cancer Gene Ther. 2002;9:819–24.
Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994;264:713–6.
Sun X, Hodge LM, Jones HP, et al. Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine. 2002;20:1466–74.
Kim W, Seong J, Oh HJ, et al. A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma. J Radiat Res. 2011;52:646–54.
Roilides E, Blake C, Holmes A, et al. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol. 1996;34:63–9.
Kowanko IC, Ferrante A, Harvey DP, et al. Granulocyte-macrophage colony-stimulating factor augments neutrophil killing of Torulopsis glabrata and stimulates neutrophil respiratory burst and degranulation. Clin Exp Immunol. 1991;83:225–30.
Newman SL, Gootee L. Colony-stimulating factors activate human macrophages to inhibit intracellular growth of Histoplasma capsulatum yeasts. Infect Immun. 1992;60:4593–7.
Roilides E, Mertins S, Eddy J, et al. Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type 1 and partial reversal after in vitro exposure to granulocyte-macrophage colony-stimulating factor. J Pediatr. 1990;117:531–40.
Page AV, Liles WC. Colony-stimulating factors in the prevention and management of infectious diseases. Infect Dis Clin North Am. 2011;25:803–17.
Steinwede K, Tempelhof O, Bolte K, et al. Local delivery of GM-CSF protects mice from lethal pneumococcal pneumonia. J Immunol. 2011;187:5346–56.
Lu H, Xing Z, Brunham RC. GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis. J Immunol. 2002;169:6324–31.
Bo L, Wang F, Zhu J, et al. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care. 2011;15:R58.
Denis M, Ghadirian E. Granulocyte-macrophage colony-stimulating factor restricts growth of tubercle bacilli in human macrophages. Immunol Lett. 1990;24:203–6.
Chroneos ZC, Midde K, Sever-Chroneos Z, et al. Pulmonary surfactant and tuberculosis. Tuberculosis. 2009;89:S10–4.
Szeliga J, Daniel DS, Yang CH, et al. Granulocyte-macrophage colony stimulating factor-mediated innate responses in tuberculosis. Tuberculosis. 2008;88:7–20.
Francisco-Cruz A, Mata-Espinosa D, Estrada-Parra S, Xing Z, Hernández-Pando R. Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage colony-stimulating factor in experimental pulmonary tuberculosis. Clin Exp Immunol. 2013;171:283–97.
Marlow N, Morris T, Brocklehurst P, et al. A randomised trial of granulocyte-macrophage colony-stimulating factor for neonatal sepsis: outcomes at 2 years. Arch Dis Child Fetal Neonatal Ed. 2013;98(1):F46–53.
Mera S, Tatulescu D, Cismaru C, et al. Multiplex cytokine profiling in patients with sepsis. APMIS. 2011;119:155–63.
Gonzalez-Juarrero M, Hattle JM, Izzo A, et al. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control mycobacterium tuberculosis infection. J Leukoc Biol. 2005;77:914–22.
Lang RA, Metcalf D, Cuthbertson RA, et al. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell. 1987;51:675–86.
Zhang X, Divangahi M, Ngai P, et al. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine. 2007;25:1342–52.
Ryan AA, Wozniak TM, Shklovskaya E, et al. Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs. J Immunol. 2007;179:18–24.
Nambiar JK, Ryan AA, Kong CU, et al. Modulation of pulmonary DC function by vaccine-encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection. Eur J Immunol. 2010;40:153–61.
Dou J, Tang Q, Yu F, et al. Investigation of immunogenic effect of the BCG priming and Ag85A- GM-CSF boosting in Balb/c mice model. Immunobiology. 2010;215:133–42.
Zhang X, Divangahi M, Ngai P, et al. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine. 2007;25:1342–52.
Wang J, Zganiacz A, Xing Z. Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation. Vaccine. 2002;20:2887–98.
Wang H, Zhang G, Wen Y, et al. Intracerebral administration of recombinant rabies virus expressing GM-CSF prevents the development of rabies after infection with street virus. PLoS One. 2011;6:e25414.
Li N, Yu YZ, Yu WY, et al. Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant. Immunopharmacol Immunotoxicol. 2011;33:211–9.
Grabstein KH, Urdal DL, Tushinski RJ, et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science. 1986;232:506–8.
Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med. 2006;354:2034–45.
Acknowledgments
A.F.C., O.R.E., and M.A.S., are scholarship holders from the National Council for Science and Technology (CONACYT), Mexico. Point of view and discussion from León Islas is gratefully acknowledged. The graphic design expertise from Ariadna Méndez is gratefully acknowledged. The authors declare not to have any conflict of interest related to publishing this article.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Francisco-Cruz, A., Aguilar-Santelises, M., Ramos-Espinosa, O. et al. Granulocyte–macrophage colony-stimulating factor: not just another haematopoietic growth factor. Med Oncol 31, 774 (2014). https://doi.org/10.1007/s12032-013-0774-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-013-0774-6